S. Sari, Wening Tri Mawanti, Dewi Martalena, E. Listiyaningsih, Rizkyana Avissa, Rini Latifah, W. Sukarya
{"title":"Pro-inflammatory cytokine (IL-6) and total count lymphocyte profiles in COVID-19 patients with different severity levels","authors":"S. Sari, Wening Tri Mawanti, Dewi Martalena, E. Listiyaningsih, Rizkyana Avissa, Rini Latifah, W. Sukarya","doi":"10.19106/jmedsci005303202101","DOIUrl":null,"url":null,"abstract":"COVID-19 is caused by the SARS-CoV-2 infection that attacked the human respiratory system. In severe conditions it causes pneumonia, kidney failure, acute respiratory distress syndrome (ARDS) and even death. The SARS-CoV-2 infection triggers the immune cells to secrete an excess of pro-inflammatory cytokines that lead to cytokine storm. It is believed to become one of the mechanisms that cause the ARDS condition. The level of pro-inflammatory cytokines will differ with each case severity. This study aimed to evaluate the profile of pro-inflammatory cytokines in COVID-19 patients with different severity. Therefore, it could be used as a therapeutic approach for cytokine storm conditions. It was a cross sectional study using plasma samples of COVID-19 patients from Jakarta Islamic Hospital Pondok Kopi and Dr. M. Goenawan Partowidigdo Hospital Cisarua Indonesia. The COVID-19 patients with severe (n=20) and mild to moderate (n=25) severity were involved in this study. As a negative control plasma sample from healthy subjects (n=13) was used. Plasma IL-6 levels were measured using the ELISA technique and plasma lymphocyte levels were measured using a hematology analyzer. The results showed that no significant difference between severity and gender was observed (p=0.256). Meanwhile there is a significant difference in IL-6 level between negative control mild-moderate and severe categories (p=0.015). The average IL-6 level in severe categories was higher than mild-moderate and negative control categories with values 105.375 59.75 and 64.577 pg/mL respectively. This result becomes supporting evidence that there is a cytokine storm condition in severe COVID-19 patients. Furthermore, the lymphocyte level in the severe group is significantly lower than the mild to moderate group. This result may indicate lymphocytopenia in the severe group.","PeriodicalId":17474,"journal":{"name":"Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)","volume":"77 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19106/jmedsci005303202101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
COVID-19 is caused by the SARS-CoV-2 infection that attacked the human respiratory system. In severe conditions it causes pneumonia, kidney failure, acute respiratory distress syndrome (ARDS) and even death. The SARS-CoV-2 infection triggers the immune cells to secrete an excess of pro-inflammatory cytokines that lead to cytokine storm. It is believed to become one of the mechanisms that cause the ARDS condition. The level of pro-inflammatory cytokines will differ with each case severity. This study aimed to evaluate the profile of pro-inflammatory cytokines in COVID-19 patients with different severity. Therefore, it could be used as a therapeutic approach for cytokine storm conditions. It was a cross sectional study using plasma samples of COVID-19 patients from Jakarta Islamic Hospital Pondok Kopi and Dr. M. Goenawan Partowidigdo Hospital Cisarua Indonesia. The COVID-19 patients with severe (n=20) and mild to moderate (n=25) severity were involved in this study. As a negative control plasma sample from healthy subjects (n=13) was used. Plasma IL-6 levels were measured using the ELISA technique and plasma lymphocyte levels were measured using a hematology analyzer. The results showed that no significant difference between severity and gender was observed (p=0.256). Meanwhile there is a significant difference in IL-6 level between negative control mild-moderate and severe categories (p=0.015). The average IL-6 level in severe categories was higher than mild-moderate and negative control categories with values 105.375 59.75 and 64.577 pg/mL respectively. This result becomes supporting evidence that there is a cytokine storm condition in severe COVID-19 patients. Furthermore, the lymphocyte level in the severe group is significantly lower than the mild to moderate group. This result may indicate lymphocytopenia in the severe group.